Background. A 17-year-old white male with Crohn's disease who was receiving maintenance infusions of the anti-tumor necrosis factor (TNF) agent, infliximab, presented with a new-onset psoriasiform ...

Patients with Crohn's disease who lose some or all of their initial therapeutic response to infliximab can benefit from dose intensification. Regueiro et al. retrospectively analyzed 293 patients ...

The licensed dose of infliximab in AS (5 mg/kg at 6-week intervals, following loading infusions at 0, 2, and 6 weeks) is higher than for rheumatoid arthritis (RA) (3 mg/kg at 8-week intervals).

In our study 7/19 (37%) in the infliximab group received more than one infusion. The outcomes of these patients are as follows: two patients required colectomy after 106 and 291 days while the ...

More arthralgia occurred with vedolizumab than infliximab (12.1% vs 3.8%) but less infusion reactions (none vs 5.1%) More serious AEs occurred with infliximab (18.5%) than vedolizumab (6.4%), but ...

Johnson & Johnson’s inflammatory diseases blockbuster Remicade (infliximab) faces further US competition after the FDA granted a licence for Samsung Bioepis’ biosimilar, Renflexis, in all the ...

Merck, Sharp and Dohme's (MSD) inflammatory diseases blockbuster Remicade (infliximab) faces further biosimilar competition after Samsung Bioepis' rival, Flixabi, was approved in Europe.

Celltrion, Inc. today announced that six abstracts will be presented at the 2025 Digestive Disease Week ® (DDW) Annual Meeting, taking place May 3-6 in San Diego, California. The oral and poster ...